GPAS is already a collaboration of multiple universities and academic institutes. Its scope will grow with new partners and allow easy data sharing between countries and establishments. It will also enable identification of similar strains and hopefully lead to ongoing collaborative research in epidemiology, therapeutics and diagnostics of multiple pathogens starting with SARS-CoV02 and TB.
Local healthcare institutes with the ability to sequence SARS-CoV-2 will be able to get rapid data analysis to enable early, on the ground, interventions once VOCs are identified. GPAS will also influence therapeutic and drug treatment options on a same-day basis.
GPAS will be a powerful tool for public health agencies across the globe. It will allow them to quickly identify features such as VOCs and antimicrobial resistance as they develop, and will be easily identifiable.
with minimal metadata and removal of all personal identifiable information.
storage of data, with multiple data-sharing options, to protect autonomous control over information and health data.
service donated by Oracle to drive interoperability, speed and standardised approach.
for academic and research labs in low- and middle-income countries.
offering first-of-its-kind standardised processing anywhere in the world, plus ability to compare data and store/link data in global repositories.
technology can incorporate sequences from Oxford-Nanopore and Illumina with other platforms to be added.
meaning the first use case is SARS-CoV-2 but will expand to TB with other pathogen candidates also being considered.